Alex Gallo, a researcher from the University of Western Australia has recently completed a pilot study and published his findings which outline the impacts of flumazenil as a treatment for generalised anxiety disorder (GAD). Alex has been working with Fresh Start for the past three years while completing his PhD under the supervision of Professor Gary Hulse.
This pilot study concluded that subcutaneous low-dose flumazenil is a ‘safe, well-tolerated, and feasible treatment option’ for patients with GAD.
The full article which is published in the medical journal Therapeutic Advances in Psychopharmacology can be accessed here.
